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Abstract
Background: Recently, extremely low frequency electromagnetic fields (ELF-EMF) have been studied with great 
interest due to their possible effects on human health. In this study, we evaluated the effect of 4.5 mT - 120 Hz ELF-EMF 
on the development of preneoplastic lesions in experimental hepatocarcinogenesis.
Methods: Male Fischer-344 rats were subjected to the modified resistant hepatocyte model and were exposed to 4.5 
mT - 120 Hz ELF-EMF. The effects of the ELF-EMF on hepatocarcinogenesis, apoptosis, proliferation and cell cycle 
progression were evaluated by histochemical, TUNEL assay, caspase 3 levels, immunohistochemical and western blot 
analyses.
Results: The application of the ELF-EMF resulted in a decrease of more than 50% of the number and the area of γ-
glutamyl transpeptidase-positive preneoplastic lesions (P = 0.01 and P = 0.03, respectively) and glutathione S-
transferase placental expression (P = 0.01). The number of TUNEL-positive cells and the cleaved caspase 3 levels were 
unaffected; however, the proliferating cell nuclear antigen, Ki-67, and cyclin D1 expression decreased significantly (P ≤ 
0.03), as compared to the sham-exposure group.
Conclusion: The application of 4.5 mT - 120 Hz ELF-EMF inhibits preneoplastic lesions chemically induced in the rat 
liver through the reduction of cell proliferation, without altering the apoptosis process.
Background
Electromagnetic fields have been employed as useful
tools in medical diagnosis. Recently, the use of electro-
magnetic fields has been expanded to therapeutic pur-
poses because their interactions with living matter
produce effects that initiate, accelerate or inhibit biologi-
cal processes. Frequencies below 300 Hz are known as
extremely low frequency electromagnetic fields (ELF-
EMF) and do not have enough energy to break molecular
bonds; for example, they do not cause direct damage to
DNA [1]. Additionally, ELF-EMF are non-invasive and
non-ionizing and even have non-thermal effects on cells
and tissues. These properties have led to studies of the
influence of ELF-EMF on the development of various dis-
eases, including cancer.
While some researchers associate ELF-EMF exposure
with carcinogenesis [2,3], other studies of experimental
models and human cancers have shown that ELF-EMF do
not increase the risk of several cancer types, including
liver cancer, and that treatment with tumor-specific fre-
quencies is feasible and well tolerated and may have bio-
logical efficacy in patients with advanced tumors [4-6].
Moreover, the exposure of female C3H/HeJ mice bearing
mammary adenocarcinoma to a frequency of 120 Hz at
intensities of 4 and 5 mT resulted in a significant reduc-
tion in the growth of the tumors, which is a phenomenon
associated with angiogenesis inhibition [7]. The exposure
of female athymic nude mice with human breast cancer
xenografts to a frequency of 120 Hz with an intensity of
15 mT, either alone or in combination with gamma radia-
tion, resulted in decreased growth and reduced vascular-
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ization of the tumors [8]. Similarly, the effect of 50 Hz at
0.5 μT and 0.5 mT on the development of chemically
induced foci in rat livers showed a slight inhibition of
their formation [9]. This evidence that ELF-EMF inhibit
carcinogenesis is not convincing, and the exact molecular
mechanisms that account for its effects must be validated.
The purpose of this study was to use the modified resis-
tant hepatocyte model (MRHM), which induces a rapid
proliferation of altered hepatocytes to form preneoplastic
lesions in the rat liver [10], as a reliable model to seek
information concerning to the effects of ELF-EMF on
hepatocarcinogenesis. We hypothesized that the develop-
ment of preneoplastic lesions chemically induced in rat
livers could be affected by 4.5 mT - 120 Hz ELF-EMF
exposure. Our results showed that this exposure clearly
inhibits the development of preneoplastic lesions through
the reduction of cell proliferation, a characteristic altera-
tion that has been found previously in the induction of
experimental hepatocarcinogenesis [11,12]. Thus, our
finding could be the basis for the design of strategies and
clinical applications of ELF-EMF for the treatment of
hepatocellular carcinoma.
Methods
Reagents and antibodies
N-Diethylnitrosamine (DEN), 2-acetylaminofluorene
(2AAF), γ-glutamyl-4-methoxy-2-naphthylamine
(GMNA), glycyl-glycine and 4-benzoylamino-2,5-
diethoxybenzene-diazonium chloridae hemi [zinc chlo-
ride] salt (Fast Blue BB salt) were obtained from SIGMA
(St. Louis, MO, USA). A DeadEnd™ Colorimetric TUNEL
System kit was purchased from Promega (Madison, WI,
USA), and a complete proteases inhibitor cocktail was
acquired from Roche (Indianapolis, IN, USA). Anti-gluta-
thione S-transferase placental (GST-p) and Universal
LSAB™ plus kit were obtained from DAKO (Carpinteria,
CA, USA). Anti-PCNA and DAB Plus Substrate kit were
purchased from Zymed (San Francisco, CA, USA). Anti-
cyclin D1 was obtained from Bio SB (Santa Barbara, CA,
USA), anti-Ki-67 was acquired from Cell Marque Corp
(Austin, TX, USA), anti-caspase 3 was purchased from
Cell Signaling (Danvers, MA, USA), and anti-actin was
obtained from CINVESTAV, Mexico City.
Experimental design
Male Fischer-344 rats weighing 160 to 200 g, obtained
from the Production Unit of Experimental Laboratory
Animals (UPEAL-CINVESTAV, México D.F., Mexico),
were fed ad libitum and housed in a controlled environ-
ment (12 h light/12 h dark cycle; room temperature was
maintained at 22 ± 2°C, with relative humidity at 55 ±
10%). The experiments were performed in accordance
with the guidelines of the Institutional Animal Care and
Use Committee of the Official Mexican Standard NOM-
062-ZOO-1999. For carcinogenic treatment, MRHM was
used [11,13]. The rats were initiated with a necrogenic
dose of DEN (200 mg/kg of body weight, i.p.), and 7 days
later, 2AAF was orally administered at 20 mg/kg per dose
for 3 consecutive days before a partial hepatectomy (PH)
as shown Figure 1. Three groups of 6 rats each one, were
randomized. The first group, which was used as the nor-
mal control did not receive treatment, NC group. The
second group, which was used as the positive control for
carcinogenesis, was subjected to the carcinogenic treat-
ment and was kept under the same stress conditions
without electromagnetic field exposure (sham-exposure)
throughout the experiment; in this case the equipment
was turned off, CT group. The third group, additionally
to the carcinogenic treatment, was exposed to ELF-EMF
according to "Animal exposure" section, CTF group. For
this group, the administrations of DEN, 2AAF and PH
were carried out before ELF-EMF exposure schedule.
The animals were sacrificed on day 25 after carcinogene-
sis initiation (Figure 1). All of the rats from each group
were used for all determinations. Biochemical and molec-
ular evaluations were performed under blind conditions
by expert people not involved in the animal exposure.
System of ELF-EMF exposure
A uniform and homogeneous ELF-EMF of 120 Hz was
generated by a solenoid coil with 1900 turns in two layers
and with AWG 20-gauge copper-enameled magnetic wire
in a diameter of 25 cm, which was driven by an alternat-
ing current source (Staco Variac variable transformer
511, ISE Inc; Cleveland, OH, USA). The equipment was
controlled by a computer. The coil generated 0.1 - 4.5 mT
in its center, where the rats received the exposure. The
magnetic flux density was measured using a Gauss/Tes-
lameter (Hall effect gaussmeter F.W. BELL 5070, SYPRIS
Test & Mesurements; Orlando, FL, USA); the signal
parameters were monitored by an inductive coil that was
connected in parallel to a resistance by an oscilloscope
(Tektronix TDS2024, TEKTRONIX Inc; Beaverton, OR,
USA). The current flow was measured by an alternating
current meter that was connected in series with the sole-
noid (Digital multimeter Tech TM-178, Techman Elec-
tronics Inc; La Verne, CA, USA). When the animals were
exposed or had sham-exposure, the temperature inside
the solenoid was monitored by a temperature sensor
(LM35 IC: Integrated Circuit, National Semiconductor
Corporation Americas; Santa Clara, CA, USA). The tem-
perature sensor location and the shape of signal wave are
shown in Figure 2.
Animal exposure
During the exposure, CTF group was divided in two sub-
groups of three rats each one and placed in a Plexiglas
cage (16 × 16 × 25 cm) inside of solenoid. Each subgroupJiménez-García et al. BMC Cancer 2010, 10:159
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was exposed to 4.5 mT - 120 Hz ELF-EMF for 50 min
daily as shown Figure 1; the first group was exposed from
10:00 - 10:50 h and the second was from 12:00 - 12:50 h,
alternating them on this schedule, during 32 consecutive
days (from 7 days before carcinogenic treatment until 25
days after). After exposure all animals were returned to
their home cages. We decided to apply the ELF-EMF
from 7 days before starting the carcinogenic treatment,
because our initial approach was to assess its effect on the
inhibition of preneoplastic lesions development in rat
liver, as a strategy to prevent the disease in the early
stages of its development.
GGT histochemical staining
Histological liver sections of 15 μm were obtained in a
cryostat (Slee Cryostat MTC, Germany). For each animal
3 tissue sections were analyzed randomly. The preneo-
plastic lesions in the rat livers were observed by the
detection of γ-glutamil transpeptidase (GGT) activity as
previously described [14]. Briefly, sections were fixed in
absolute ethanol for 10 min at -20°C; the fixation was fol-
lowed by the addition of GMNA, glycyl-glycine and Fast
Blue BB salt in a 100 mM Tris base for 30 min at room
temperature. Subsequently, the staining was fixed with
cupric sulfate for 2 min. Finally, images of the liver tissue
were captured with a digital camera in a microscope, and
the GGT-positive lesions were quantified by image analy-
sis software (analySIS Soft Imaging System GmbH). The
experimental procedure was carried out at the same time
for all comparative groups.
TUNEL assay and immunohistochemical analysis
Liver tissue sections, 4 μm thick, were deparaffinized and
hydrated gradually. DNA fragmentation was determined
by a Colorimetric TUNEL System kit, according to the
manufacturer's instructions and a tissue treated with
DNase I was used as a positive control. For immunohis-
tochemical analyses 4 sequential sections per rat were
analyzed; antigens were unmasked by immersing the sec-
tions in 0.1 M sodium citrate buffer (pH 6) in a heated
water bath for 15 min. Then, endogenous peroxidase
activity was blocked with 0.3% H2O2 in methanol. Pri-
mary antibodies anti-GST-p, anti-PCNA, anti-Ki-67 and
anti-cyclin D1 were incubated overnight at 4°C. After a
standard staining protocol using Universal LSAB™ plus
kit and a DAB Plus Substrate kit as the chromogen, the
sections were lightly counterstained with hematoxylin,
dehydrated and mounted. As a positive control for
PCNA, Ki-67 and cyclin D1, liver sections from one rat
subjected to partial hepatectomy and sacrificed after 24
h, were used to observe high proliferation levels. Tissues
images were captured by optical microscopy (Olympus
1X70, Olympus Europa GmbH, Hamburg, Germany).
Then, positive cells for PCNA, Ki-67 and cyclin D1 were
quantified in ten randomly selected fields (magnification
10×) per individual sample, and the numbers of positive
cells/mm2 were calculated using image analysis software
(analySIS Soft Imaging System GmbH). For detection of
each protein, the immunostaining protocol was carried
out at the same time for all comparative groups.
Figure 1 Schematic representation of the carcinogenic treatment and ELF-EMF exposure. The sham-exposure or exposure to ELF-EMF was ap-
plied before and during carcinogenic treatment, as indicated in schemes of CT and CTF groups, respectively. NC, normal control; CT, carcinogenic 
treatment and sham-exposure; CTF, carcinogenic treatment plus ELF-EMF exposure. S, sacrifice; DEN, N-diethylnitrosamine; 2AAF, 2-acetylaminofluo-
rene; PH, partial hepatectomy; n = 6 for each group.Jiménez-García et al. BMC Cancer 2010, 10:159
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Western blot analysis
For proteins extraction, tissues were homogenized with
lysis buffer (10 mM Tris-Cl pH 7.4, 150 mM NaCl, 1%
Triton-X100 and proteases inhibitor cocktail), the cell
lysates were centrifuged at 15,000 g for 30 min, and the
supernatant was stored at -80°C. The procedure was per-
formed at 4°C. Proteins were separated by SDS-PAGE
and were transferred to a PVDF membrane. The protein
of interest was visualized using the indicated antibody
and a chemiluminescence system. Anti-actin was used as
a protein loading control.
Statistical analysis
Statistical differences were obtained between the carcino-
genic treatment and the carcinogenic treatment plus elec-
tromagnetic field exposure using the Student's t-test.
Data were expressed as the mean ± the standard error of
the mean (SEM). Differences were considered significant
when P < 0.05.
Results
General observations
The average body and relative liver weights of rats treated
either with CT or CTF were not different throughout the
experiment (data not shown). We also monitored the
temperature of sham-exposure (CT) or exposure (CTF)
groups during the 32 days and their values were recorded
at specific times shown in Table 1. The three degree dif-
ferential temperature between the groups was due to the
solenoid was turned off when the sham-group was
exposed.
ELF-EMF exposure inhibits preneoplastic lesions 
development
Animals subjected to the CTF protocol showed a signifi-
cant reduction in both the number and the area of GGT-
positive lesions as compared to rats subjected to the CT
protocol (Figure 3A). Table 2 shows the average value of
foci number per cm2 and the percent of area GGT-posi-
tive of each animal subjected to different experimental
protocols. The number and area of GGT-positive lesions
were reduced by 52.2 and 58.4% (P = 0.01 and P = 0.03),
respectively (Figure 3B). Similarly, western blot analysis
(Figure 3C) showed that GST-p expression was reduced
by 43.3% (P = 0.01). These results indicate that the appli-
cation of 4.5 mT - 120 Hz ELF-EMF inhibits the develop-
ment of preneoplastic lesions induced by the
hepatocarcinogenesis experimental protocol.
ELF-EMF exposure did not induce apoptosis
To evaluate the effect of ELF-EMF exposure on the apop-
tosis induction of altered hepatocytes, we used two dif-
ferent procedures applied to the three groups. First, cells
w i t h  D N A  f r a g m e n t e d  w e r e  i d e n t i f i e d  i n  t i s s u e s  b y  a
TUNEL assay. Representative tissue sections of each
treatment are depicted in Figure 4. Although a slight
increase of TUNEL-positive cells is observed in the rat
tissues of CT group (Figure 4C), these were not different
from those of rats in the NC group or those in the CTF
group (Figures 4B and 4D). According to this result, the
levels of cleaved caspase 3 were not affected by either the
CT or the CTF protocols as compared to the NC protocol
(Figure 4E). These results indicate that the application of
4.5 mT - 120 Hz ELF-EMF does not induce either DNA
fragmentation or the caspase-3 activation, indicating that
it does not promote apoptosis of altered hepatocytes.
The application of 4.5 mT - 120 Hz ELF-EMF inhibits 
proliferation during in vivo hepatocarcinogenesis
To determine whether the application of 4.5 mT - 120 Hz
ELF-EMF had an effect on cell proliferation, which is a
Figure 2 Scheme of the temperature sensor location and wave-
form signal. (A) The temperature sensor was placed in the center and 
inside of the cage where animals were sham-exposed or exposed to 
ELF-EMF. (B) Shows the waveform recorded by the oscilloscope. The 
signal was measured in the effective volume where animals were ex-
posed.Jiménez-García et al. BMC Cancer 2010, 10:159
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characteristic alteration from the induction of experi-
mental hepatocarcinogenesis, we analyzed the expression
of PCNA, which participates in replication and DNA
repair, and the expression of Ki-67, a specific replication
marker, which participates in all active phases of the cell
cycle except for the G0 phase. Moreover, PCNA and Ki-
67 are used to determinate the proliferating activity of
cancer cells [15-17]. Figure 5 shows an immunohis-
tochemical analysis of sequential sections of the same
piece of liver tissue in which the expression of PCNA and
Ki-67 proteins in GST-p-positive preneoplastic lesions
can be seen. The positive labels of PCNA and Ki-67 were
not limited to preneoplastic lesions; they were also
detected in whole tissues of the rats subjected to the CT
and CTF protocols. We observed, however, a clear reduc-
tion in the number of positively labeled cells, which was
corroborated through a quantitative analysis, as shown in
Table 3. The numbers of PCNA- and Ki-67-positive cells
per mm2 were decreased in the CTF protocol as com-
pared to the CT protocol by 87.88% (P = 0.03) and 86.97%
(P = 0.004), respectively. The nucleus labels of hepato-
cytes situated within the limits of the preneoplastic
lesions for both the CT and CTF protocols were more
intense. Figure 6 shows a western blot analysis that
revealed a similar diminution of PCNA expression
(53.62%, P = 0.03).
In order to determine the underlying mechanism of the
proliferation inhibition mediated by the application of 4.5
mT - 120 Hz ELF-EMF, we investigated the effect of this
application on cyclin D1 expression, a cell cycle regulator
protein responsible for the transition from G1- to S-
phase in both normal regulation of the cell cycle and
development of human cancers [18]. Thus, the coexis-
tence of GST-p and cyclin D1 in serial sections of tissue
was analyzed in a similar manner to that of the PCNA
and Ki-67 expressions. As shown in Figure 5 and Table 3,
Table 1: Average values of the temperature recorded during the exposure time
Treatment group
CT CTF
Time/min T/°C T/°C
0 23.7 ± 0.4 23.7 ± 0.4
25 23.9 ± 0.6 25.8 ± 0.6
35 24.2 ± 0.6 26.7 ± 0.7
45 24.0 ± 0.5 27.1 ± 0.6
50 24.1 ± 0.6 27.0 ± 0.7
All values are expressed as the mean ± SEM
Table 2: Effect of ELF-EMF exposure on foci number per cm2 and the percent of area GGT-positive
Group # animal Foci number/cm2 % of GGT-positive area
CT 1 38.71 ± 3.3 6.93 ± 0.4
2 16.31 ± 2.6 2.27 ± 0.5
3 39.22 ± 11.4 5.63 ± 1.2
4 31.42 ± 1.5 12.76 ± 0.8
5 40.51 ± 9.0 8.77 ± 1.7
6 28.66 ± 6.2 4.98 ± 1.1
CTF 1 0.65 ± 0.6 0.07 ± 0.1
2 8.13 ± 3.5 1.18 ± 0.5
3 27.45 ± 5.7 4.59 ± 0.9
4 14.85 ± 2.6 2.38 ± 0.6
5 24.40 ± 2.2 3.80 ± 0.2
6 14.50 ± 2.5 4.52 ± 0.7
Values represent the mean ± SEM of three liver sections evaluated per animal.Jiménez-García et al. BMC Cancer 2010, 10:159
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Figure 3 Effect of ELF-EMF exposure on GGT-positive lesions and GST-p expression. (A) Representative liver sections of the NC group, CT group 
and CTF group. Scale bars, 5 mm. (B) Quantification of the foci number/cm2 and percent of the GGT-positive area. (C) Western blot analysis for GST-p 
expression. GST-p was normalized with actin expression used as the loading control. The expression of NC was adjusted to one in the densitometric 
units scale. Statistically different from *NC and **CT, P < 0.05. Data are expressed as the mean ± SEM; n = 6 for each group.Jiménez-García et al. BMC Cancer 2010, 10:159
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Figure 4 Effect of ELF-EMF exposure on apoptosis. Representative liver sections of each treatment are shown. (A) Positive control tissue that was 
treated with DNase I. (B) Normal control tissue. (C) CT protocol. (D) CTF protocol; images magnification 200×. (E) Western blot analysis for cleaved 
caspase 3 levels. Caspase 3 was normalized with actin expression used as the loading control. The expression of NC was adjusted to one in the den-
sitometric units scale; n = 6 for each group.Jiménez-García et al. BMC Cancer 2010, 10:159
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the number of cyclin-D1-positive cells per mm2 was
decreased for the CTF protocol as compared to the CT
protocol by 83.13% (P = 0.008). Similar to PCNA and Ki-
67, cyclin D1-positive cells were observed in whole tis-
sues of rats that were subjected to both the CT and CTF
protocols. Figure 6 shows a western blot analysis that
confirmed the decrease of the expression of cyclin D1
(53.43%, P = 0.01). Together, these results indicate that
the inhibition of preneoplastic lesions development
induced by the application of 4.5 mT - 120 Hz ELF-EMF
in rat livers was associated with a reduction of cell prolif-
eration and suggest that ELF-EMF protects hepatocytes
from the increased proliferation induced by the carcino-
genic treatment.
Discussion
Cancer cells manifest at least six main physiological alter-
ations, which are governed by the deregulation of hun-
dreds of genes that play a role in tumor initiation and
progression and that collectively dictate malignant
growth. One of the physiological alterations of cancer
cells is their continuous growth; events associated with
the increase in cell proliferation are the loss of apoptotic
mechanisms and cell cycle continuity [19]. We have
observed that, in the early hepatocarcinogenesis induced
by the MRHM, cell proliferation is highly increased,
which affects molecules that participate in cell cycle con-
tinuity and results in the formation of preneoplastic
lesions that can progress toward hepatocellular carci-
noma [11,12,20]. In this study, rats subjected to MRHM
were exposed to 4.5 mT - 120 Hz ELF-EMF in order to
evaluate the effects of the electromagnetic fields on the
development of liver preneoplastic lesions. Our results
showed that the 4.5 mT - 120 Hz ELF-EMF exposure sig-
nificantly reduced both the number and the area of GGT-
positive lesions and GST-p expression, which are two of
the best markers for identifying preneoplastic lesions. We
have validated this phenomenon, which has been
observed previously, although only as a slight inhibition
of the liver foci [9]. Although both studies involved hepa-
tocarcinogenesis protocols, there are several differences
in the waveform of their stimulus as compared to ours,
such as the time of ELF-EMF exposure. Another impor-
tant difference is that, in our model, the hepatocarcino-
genesis treatment employed DEN, 2-AAF and PH
without any additional intervention after PH, whereas, in
the protocol used by Rannug and coworkers, phenobarbi-
tal, a promoter of cell growth, was administered continu-
ously throughout the 12 weeks of their experiment in
addition to DEN and PH. It could be the case that the
continuous promotion of altered cells in preneoplastic
nodules counteracts the effects of the ELF-EMF, which
resulted in a slight inhibition of the liver foci. In this work
we clearly validated that ELF-EMF inhibits significantly
the development of preneoplastic lesions. Even though
the effects were significant, we observed a temperature
differential between comparatives groups due to the sole-
noid was turned off when the sham-group was exposed;
thus, we can not discard that this variable could has or
not effect on the results. New experiments are required
to determine this important fact.
Some authors have suggested the therapeutic use of
ELF-EMF for cancer treatment because, in different
experimental models, ELF-EMF have been able to inhibit
the growth of cancer cell lines and tumors; however, few
in vivo experiments have been performed to investigate
the molecular mechanisms of ELF-EMF in cancer devel-
opment [8,21-24]. The anti-carcinogenic effect of ELF-
EMF could result from the inhibition of cell proliferation
and/or apoptosis induction. In vitro studies have reported
the pro-apoptotic action of ELF-EMF and that this effect
is associated with an increase in the number of annexin-
V- and TUNEL-positive cells and caspase 3 activity
[21,25]. Previously, we observed that our hepatocarcino-
genesis model does not induce apoptosis of altered hepa-
tocytes evaluated at different points until 25 days after
cancer initiation [11,12]. Using this model, we evaluated
the pro-apoptotic effect of ELF-EMF exposure through
TUNEL assays and cleaved caspase 3 levels, but we did
not find any differences in the apoptosis status between
Table 3: Number of PCNA-, Ki-67- and cyclin D1-positive cells/mm2
Cell number/mm2*
Treatment group PCNA Ki-67 cyclin D1
NC 22.36 ± 1.05 7.02 ± 3.24 49.31 ± 2.07
CT 492.03 ± 76.36a 192.74 ± 15.49a 265.39 ± 23.95a
CTF 59.59 ± 10.38b 25.11 ± 3.32b 44.75 ± 5.36b
*Mean ± SEM from ten fields per rat tissue, captured at 100× magnification, n = 3
aStatistically different from the NC group, P < 0.05
bStatistically different from the CT group, P < 0.05Jiménez-García et al. BMC Cancer 2010, 10:159
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the CT and CTF groups. These data indicate that the
application of 4.5 mT - 120 Hz ELF-EMF does not induce
either DNA fragmentation or the caspase-3 activation,
indicating that it does not promote apoptosis of altered
hepatocytes.
During induction of liver cancer using the MRHM, the
proliferation of hepatocytes increases; therefore, we
tested whether 4.5 mT - 120 Hz ELF-EMF exposure
affects the expression of PCNA, Ki-67 and cyclin D1. We
showed that ELF-EMF exposure decreased the expres-
sion of these proteins, suggesting that the ELF-EMF
Figure 5 Immunohistochemical analysis of GST-p, PCNA, Ki-67 and cyclin D1 expression. Four serial liver sections from each treatment are 
shown in columns. Immunostaining for each protein is displayed in rows. GST-p detection shows the preneoplastic lesions for localization of PCNA, 
Ki-67 and cyclin D1 (CD1) expression. NC, normal control; CT, carcinogenic treatment; CTF, carcinogenic treatment plus ELF-EMF exposure; images 
magnification 200×; n = 6 for each group.Jiménez-García et al. BMC Cancer 2010, 10:159
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interferes with both the altered cell cycle continuity and
DNA synthesis induced by chemical hepatocarcinogene-
sis. The effects on cyclin D1 expression and other pro-
teins of the cell cycle have also been observed in human
diploid amniotic fluid cells, where 1 mT - 50 Hz exposure
diminished cyclin D1 expression though a significant cell
arrest in the G2/M phase was induced when the electro-
magnetic field was applied in combination with different
doses of ionizing radiation [26].
Since cells in liver preneoplastic lesions have a growth
advantage as compared to the surrounding tissue, we also
investigated whether PCNA, Ki-67 and cyclin D1 expres-
sions were limited to the area of the lesions that were
GST-p positive. We found that these proteins were
expressed by cells from the whole tissue, including the
preneoplastic lesions and surrounding tissue, although
we found a significant reduction in the protein expression
of tissues from rats subjected to the CTF protocol as
compared to those of the CT protocol. Based on immu-
nohistochemical analysis, the diminutions in the positive
cells number for three proteins were more than 80%. This
effect was confirmed by western blot analysis for PCNA
and cyclin D1 proteins where there was a reduction in the
n u m b e r  o f  p o s i t i v e  c e l l s  i n  m o r e  t h a n  5 0 % .  T o g e t h e r ,
these results show that 4.5 mT - 120 Hz ELF-EMF expo-
sure affects the development of preneoplastic lesions of
the liver and that this effect is associated with the inhibi-
tion of the proliferation process.
The correlation between the presence of Ki-67, PCNA
and cyclin D1 has already been studied; while PCNA par-
ticipates in replication and DNA repair and is also closely
associated with the cell cycle machinery, Ki-67 is a spe-
cific replication marker associated with cell cycle entry
given that participates in all active phases of the cell cycle
except for the G0 phase [15,16,27]. We evaluated their
expression by immunohistochemistry and found that
ELF-EMF altered the amounts of positive cells expressing
these proteins and we concluded that this effect is associ-
ated with the diminishing of cell proliferation. However,
given that PCNA takes part else in DNA repair and that
the amount of PCNA-positive cells were larger than Ki-
67 (see Table 3); if we assume that all Ki-67-positive cells
wer e also PCNA-positive, it is striking t o observe t ha t
from the subtraction between them ([PCNA - Ki67]), the
number of remaining PCNA-positive cells is similar to
the number of cyclin D1-positive cells. Thus, the remain-
ing PCNA-positive cells would be involved in DNA
repair, but not in proliferation processes. A similar analy-
sis was reported in human myocytes, where was observed
that TUNEL-positive cells can simultaneously express
PCNA, but not Ki-67 [28]. This also could explain why
the slight increase of TUNEL-positive cells observed in
CT group, was not confirmed by cleaved caspase-3 detec-
tion. Together this information, suggests that the ELF-
EMF could be altering the amount of cells bearing DNA
damage in the MRHM model. Further studies are
required to determine the nature of this possible associa-
tion.
In our laboratory, we showed that the celecoxib, a non-
steroidal anti-inflammatory drug, inhibits the develop-
ment of preneoplastic lesions through anti-proliferative
mechanisms without inducing the apoptosis process [12],
similar to the 4.5 mT - 120 Hz ELF-EMF exposure
showed in this work. Even though celecoxib is a synthetic
molecule and ELF-EMF is an interaction energy, both
have anti-carcinogenic effects; however, when celecoxib
is administered at high doses increases the risk of cardio-
vascular events [29]. Given the efficacy shown by ELF-
EMF exposure, our results motivate the evaluation of the
synergic effect of ELF-EMF in combination with low
doses of celecoxib, which could increase their efficacy
and minimize the cardiovascular damage [30,31]; this
combination of treatments could have an analogous
result to the combination of low doses of X-ray or gamma
radiation plus ELF-EMF exposure [8,25].
ELF - EM F  a r e  a b l e  t o  i n t e r a ct  wi t h  m o vi n g  e l ect r o n s
and increase electron transfer rates in chemical reactions
[32]. However, the interaction of ELF-EMF exposure with
biological systems, from a physical point of view, remains
unclear. Nevertheless, a biophysical model has recently
been hypothesized. In this model, the action mechanism
of the electromagnetic fields in cells occurs through the
forced vibration of each of the free ions that exist on both
sides of all plasma membranes and that can move across
of them using transmembrane proteins, which disrupt
Figure 6 Effect of ELF-EMF exposure on PCNA and cyclin D1 ex-
pression. Western blot analysis for PCNA and cyclin D1 expressions. 
Both expressions were normalized with actin expression used as the 
loading control. The expression of NC was adjusted to one in the den-
sitometric units scale. Statistically different from *NC and **CT, P < 0.05. 
Data are expressed as the mean ± SEM; n = 6 for each group.Jiménez-García et al. BMC Cancer 2010, 10:159
http://www.biomedcentral.com/1471-2407/10/159
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the electrochemical balance of the plasma membrane
and, therefore, the whole function of the cell [33]. Fur-
thermore, evaluations in experimental models have been
established that the electromagnetic fields are able to
modulate the intracellular calcium (Ca2+) when cellular
homeostasis is disrupted [34]. Calcium is a highly versa-
tile intracellular signal that can regulate many different
cellular functions, whether normal or pathological; thus,
the consequences of Ca2+ signaling depend of steady state
between Ca2+  influx, efflux, and storage [35]. Cancer
development takes place through rapid proliferation and
the continuous increase of altered cells that modify the
cellular environment [19], including the flow of ionic
charges across the cell membrane, such as Ca2+ flow.
Given that several blockers of Ca2+ entry inhibit tumor
growth [36], we cannot discount that ELF-EMF could be
regulating Ca2+ flow in the cells. Therefore, we can specu-
late that the interaction of ELF-EMF with ion flows in the
membranes of altered cells interferes with processes that
are involved in the development of liver preneoplastic
lesions, such as the changes in cell cycle continuity
induced by DEN, 2AAF and PH. Finally, another possible
action mechanism of ELF-EMF could be at radical chem-
istry levels; in this way we currently are designing experi-
ments to determine this possible effect on electron
transfer rates involved in the oxidative stress generated
throughout the chemical hepatocarcinogenesis progres-
sion and we are also making a quantum-mechanical
model, using radical pairs mechanism theory, that could
explain this process.
Conclusion
Our results indicate that the application of 4.5 mT - 120
Hz ELF-EMF affects the early carcinogenesis chemically
induced in rat livers, through the reduction of PCNA, Ki-
67 and cyclin D1 expressions without inducing apoptosis,
which suggests that ELF-EMF regulate cellular homeo-
stasis and inhibit the development of preneoplastic
lesions. Finally, considering that hepatocellular carci-
noma is a common form of cancer and that its incidence
around the world remains high [37], this finding could be
the basis for the design of strategies and clinical applica-
tions of ELF-EMF to treat this disease, aimed primarily at
high-risk populations.
List of abbreviations
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